Conclusions Ezetimibe monotherapy ( 10 mg/day ) showed a small ( 7.06 % ) but statistically significant reduction in the plasma levels of Lp(a ) in patients with primary hypercholesterolemia .
According to current literature , this magnitude of reduction seems to have no clinical relevance .
Background and Aims Ezetimibe reduces plasma low-density lipoprotein cholesterol ( LDL-C ) levels by up to 20 % .
However , its effect on plasma lipoprotein(a ) [ Lp(a ) ] concentrations in patients with primary hypercholesterolemia has not been defined .
Objective Therefore , we performed a systematic review and meta- analysis to assess this effect based on the available r and omized controlled trials ( RCTs ) .
Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia.
AIM Ezetimibe is a novel cholesterol absorption inhibitor that reduces the level of low-density lipoprotein (LDL)-cholesterol ( C ) . The effects of ezetimibe on remnant-like particle (RLP)-C , lipoprotein ( a ) [ Lp(a ) ] , and oxidized LDL ( Ox-LDL ) levels have not been examined . METHODS Fifty patients with dyslipidemia were treated with 10 mg/day of ezetimibe . At baseline and 12 weeks after treatment with ezetimibe , we measured the levels of RLP-C , Lp(a ) , Ox-LDL , and high-sensitivity C-reactive protein ( hs-CRP ) . RESULTS The mean levels of total cholesterol ( TC ) , LDL-C , triglycerides ( TG ) , and apolipoprotein ( apo ) B , respectively , showed a significant decrease from 229+/-39 to 191+/-37 mg/dL ( -16 % , p<0.0001 ) , from 151+/-34 to 118+/-33 mg/dL ( -22 % , p<0.0001 ) , from 162+/-82 to 135+/-55 mg/dL ( -7 % , p<0.01 ) , and from 116+/-22 to 94+/-21 mg/dL ( -18 % , p<0.0001 ) after 12 weeks of treat-ment with ezetimibe . The mean level of RLP-C and median level of hs-CRP also decreased signifi-cantly from 6.8+/-4.0 to 4.8+/-2.5 mg/dL ( -21 % , p<0.0001 ) and from 0.6 to 0.4 mg/L ( -33 % , p<0.05 ) . The median level of Lp(a ) decreased significantly from 14 to 10 mg/dL ( -29 % , p<0.05 ) in patients treated with ezetimibe monotherapy . CONCLUSIONS Ezetimibe was effective for reducing the levels of TC , LDL-C , TG , and RLP-C.  Ezeti-mibe could be a potential therapeutic option for decreasing the Lp(a ) level
Conclusions Ezetimibe monotherapy ( 10 mg/day ) showed a small ( 7.06 % ) but statistically significant reduction in the plasma levels of Lp(a ) in patients with primary hypercholesterolemia .
According to current literature , this magnitude of reduction seems to have no clinical relevance .
Background and Aims Ezetimibe reduces plasma low-density lipoprotein cholesterol ( LDL-C ) levels by up to 20 % .
However , its effect on plasma lipoprotein(a ) [ Lp(a ) ] concentrations in patients with primary hypercholesterolemia has not been defined .
Objective Therefore , we performed a systematic review and meta- analysis to assess this effect based on the available r and omized controlled trials ( RCTs ) .